DDX17 Protein (p72)

DDX17 Protein (p72)

Overview

DDX17 (also known as p72) is a member of the DEAD-box (Asp-Glu-Ala-Asp) RNA helicase family, belonging to the SF2 superfamily of RNA helicases. This protein is encoded by the DDX17 gene (also known as P72) and is a multifunctional enzyme involved in various aspects of RNA metabolism, including transcription regulation, alternative splicing, RNA processing, miRNA biogenesis, and RNA stability. DDX17 has emerged as a critical player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), where it interacts with disease-associated proteins and participates in pathways central to neuronal survival and function.

The protein's involvement in neurodegeneration was first highlighted by studies showing that DDX17 regulates the alternative splicing of ALS-associated genes and later confirmed by demonstrations of its physical interaction with [alpha-synuclein](/proteins/alpha-synuclein), the hallmark protein of Parkinson's disease. These findings have positioned DDX17 as both a potential therapeutic target and a biomarker candidate for neurodegenerative disorders.

DDX17 Protein (p72)

Overview

DDX17 (also known as p72) is a member of the DEAD-box (Asp-Glu-Ala-Asp) RNA helicase family, belonging to the SF2 superfamily of RNA helicases. This protein is encoded by the DDX17 gene (also known as P72) and is a multifunctional enzyme involved in various aspects of RNA metabolism, including transcription regulation, alternative splicing, RNA processing, miRNA biogenesis, and RNA stability. DDX17 has emerged as a critical player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), where it interacts with disease-associated proteins and participates in pathways central to neuronal survival and function.

The protein's involvement in neurodegeneration was first highlighted by studies showing that DDX17 regulates the alternative splicing of ALS-associated genes and later confirmed by demonstrations of its physical interaction with [alpha-synuclein](/proteins/alpha-synuclein), the hallmark protein of Parkinson's disease. These findings have positioned DDX17 as both a potential therapeutic target and a biomarker candidate for neurodegenerative disorders.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">DDX17 Protein Information</th></tr>
<tr><td><b>Protein Name</b></td><td>DDX17 (p72, RNA helicase DDX17)</td></tr>
<tr><td><b>Gene Symbol</b></td><td><a href="/genes/ddx17">DDX17</a></td></tr>
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/Q9NYV5">Q9NYV5</a></td></tr>
<tr><td><b>PDB Structure</b></td><td>5JAJ, 5JB4, 6DVZ</td></tr>
<tr><td><b>Molecular Weight</b></td><td>72 kDa</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Nucleus, cytoplasm, stress granules</td></tr>
<tr><td><b>Protein Family</b></td><td>DEAD-box RNA helicase family (SF2)</td></tr>
<tr><td><b>Aliases</b></td><td>p72, P72, DDX17, DEAD-box polypeptide 17</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Structure

Domain Architecture

DDX17 possesses the characteristic structure of DEAD-box RNA helicases, consisting of two highly conserved RecA-like domains separated by a flexible linker [@rothenburg2019]:

• N-terminal Domain (NTD): Contains the Q motif (residues 39-45), which is involved in ATP binding and discrimination between ATP and GTP. The Q motif also helps coordinate ATP hydrolysis and determines the direction of nucleic acid unwinding.
• Motif I (Walker A, residues 101-108): The conserved AxxGxGKT sequence is responsible for ATP binding. This motif forms the phosphate-binding loop essential for nucleotide triphosphate interaction.
• Motif II (Walker B, residues 165-169): The DEAD motif gives the protein family its name. The Asp-Glu-Ala-Asp sequence is critical for ATP hydrolysis, with the Asp residues serving as catalytic residues.
• Motif III (residues 215-219): Involved in ATP-dependent RNA unwinding and translocation.
• Motif IV (residues 262-268): Participates in RNA binding and helicase activity.
• Motif V (residues 297-305): Contains the Q-motif and contributes to RNA binding affinity.
• Motif VI (residues 353-360): The HRIGRNVR motif is essential for ATP hydrolysis and helicase function.

C-terminal Domain

The C-terminal domain of DDX17 contains regulatory elements that modulate the protein's activity:

• C-terminal Extension: An acidic tail region involved in protein-protein interactions with transcription factors and co-activators.
• Serine/Threonine Phosphorylation Sites: Multiple phosphorylation sites regulate DDX17's subcellular localization and activity. The protein can be phosphorylated by various kinases, including [LRRK2](/genes/lrrk2) in the context of Parkinson's disease [@zhou2021].

Structural Flexibility

DDX17 exhibits significant conformational flexibility that allows it to function in diverse cellular processes. The two RecA-like domains can adopt different relative orientations, enabling the protein to transition between active and inactive states during the helicase cycle. This flexibility is crucial for the protein's ability to interact with multiple binding partners and participate in various RNA-related processes.

Normal Function

Transcriptional Regulation

DDX17 functions as a transcriptional co-activator for numerous transcription factors, playing a central role in gene expression regulation:

• p53 Activation: DDX17 interacts with p53 and its co-activators to enhance p53-mediated transcription, participating in DNA damage response and cell cycle regulation.
• NF-κB Signaling: DDX17 serves as a co-activator for NF-κB, modulating the expression of inflammatory and anti-apoptotic genes. This function has implications for neuroinflammation in neurodegenerative diseases [@geng2020].
• Estrogen Receptor Signaling: DDX17 enhances estrogen receptor (ERα and ERβ) transcriptional activity, influencing hormone-responsive gene expression. While classically associated with breast cancer, this pathway has relevance to neuroprotection in certain brain regions.
• MyoD and Muscle Differentiation: DDX17 participates in muscle differentiation by co-activating MyoD and other myogenic transcription factors.
• c-Myc Regulation: DDX17 interacts with c-Myc and participates in Myc-dependent transcriptional programs.

Alternative Splicing Regulation

One of DDX17's most important functions is its role in regulating alternative splicing [@kamelgarn2018]:

• Spliceosome Component: DDX17 associates with the spliceosome and modulates the splicing of specific pre-mRNA transcripts.
• Splicing Factor Recruitment: The protein helps recruit splicing factors to specific splice sites, influencing which exons are included or excluded in the mature mRNA.
• Tissue-Specific Splicing: DDX17 exhibits tissue-specific splicing patterns, with particularly important functions in neuronal tissues where alternative splicing is highly prevalent.
• Neurological Gene Targets: DDX17 regulates the splicing of numerous neuronal genes, including those involved in synaptic function, axonal guidance, and neuronal development.

miRNA Biogenesis

DDX17 participates in the microRNA (miRNA) processing pathway:

• Primary miRNA Processing: DDX17 interacts with the microprocessor complex (Drosha-DGCR8) to facilitate the processing of primary miRNA transcripts into precursor miRNAs.
• Alternative Processing: The protein can influence which primary miRNAs are processed, contributing to the cell-type specific miRNA expression patterns.
• miRNA Function: By modulating miRNA biogenesis, DDX17 indirectly regulates the expression of numerous target genes through post-transcriptional mechanisms.

RNA Stability and Translation

DDX17 influences mRNA stability and translation:

• mRNA Stabilization: DDX17 can bind to specific mRNAs and protect them from degradation, influencing transcript half-life.
• Translation Regulation: DDX17 participates in translational control, modulating the efficiency of protein synthesis from specific mRNAs.
• Ribosome Biogenesis: DDX17 has been implicated in ribosome biogenesis, indirectly affecting overall protein synthesis capacity.

Stress Granule Formation

Under cellular stress conditions, DDX17 localizes to stress granules [@yang2022]:

• Stress Response: DDX17 is recruited to stress granules in response to various cellular stresses, including oxidative stress and heat shock.
• mRNA Sequestration: In stress granules, DDX17 helps sequester specific mRNAs, temporarily inhibiting their translation until stress is relieved.
• RNP Complex Formation: DDX17 participates in the formation of ribonucleoprotein (RNP) complexes that are central to stress granule assembly.

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

DDX17 has emerged as a significant player in ALS pathogenesis [@chen2022]:

Alternative Splicing Dysregulation
DDX17 regulates the alternative splicing of several ALS-associated genes. In ALS models and patient tissues, DDX17 expression and activity are altered, leading to aberrant splicing patterns that contribute to disease progression. Key targets include:

• SOD1: DDX17 influences the splicing of [SOD1](/genes/sod1) transcripts, potentially modulating the toxicity of mutant SOD1 proteins.
• TDP-43 Targets: While DDX17 itself is not a direct TDP-43 target, it participates in overlapping splicing pathways that are affected in TDP-43 proteinopathies.
• FUS Interactions: DDX17 functionally interacts with FUS (Fused in Sarcoma), another ALS-associated RNA-binding protein.

• DDX17 abnormally accumulates in stress granules in ALS models.
• Persistent stress granule localization leads to the sequestration of DDX17 away from its normal nuclear functions.
• The dysregulated stress granule behavior contributes to translational repression and mitochondrial dysfunction in motor neurons.

• Mutations in DDX17 are associated with a subset of familial ALS.
• These mutations affect DDX17's helicase activity, RNA binding capacity, or protein-protein interactions.
• DDX17-related ALS shares clinical features with other forms of ALS, including progressive motor neuron loss and typical ALS phenotypes.

Parkinson's Disease

DDX17's role in PD has been extensively characterized [@geng2020]:

Alpha-Synuclein Interaction
A landmark finding was the demonstration that DDX17 physically interacts with [alpha-synuclein](/proteins/alpha-synuclein):

• The interaction occurs in the cytoplasm and is enhanced under cellular stress conditions.
• DDX17 can modulate alpha-synuclein aggregation, with implications for Lewy body formation.
• The DDX17-alpha-synuclein interaction affects both proteins' subcellular localization and function.

• LRRK2-mediated phosphorylation of DDX17 alters its helicase activity.
• Phosphorylated DDX17 shows altered subcellular localization.
• This pathway provides a mechanistic link between LRRK2 mutations and neuronal dysfunction.

• DDX17 influences the expression of mitochondrial dynamics regulators.
• Loss of DDX17 function leads to mitochondrial fragmentation and reduced ATP production.
• Dopaminergic neurons are particularly vulnerable to DDX17 dysfunction due to their high energy demands.

• Impaired autophagic clearance of damaged proteins.
• Reduced neuronal resilience to oxidative stress.
• Progressive loss of dopaminergic neurons in the substantia nigra.

Alzheimer's Disease

While less extensively studied than in ALS and PD, DDX17 also plays roles in AD:

• DDX17 expression is altered in AD brain tissue.
• The protein participates in pathways affected by amyloid-β toxicity.
• DDX17 may influence tau phosphorylation and aggregation through indirect mechanisms.

Other Neurodegenerative Conditions

Frontotemporal Dementia (FTD)

• DDX17 is implicated in FTD pathogenesis, particularly in cases with TDP-43 pathology.
• The protein's splicing regulatory functions are affected in FTD.

• DDX17 regulates the splicing of [HTT](/genes/htt) transcripts.
• Altered DDX17 activity may contribute to mutant huntingtin toxicity.

Therapeutic Implications

Therapeutic Target Potential

DDX17 represents a promising therapeutic target for neurodegenerative diseases:

Helicase Activity Modulation

• Small molecules that enhance DDX17's helicase activity could restore proper RNA processing.
• Alternatively, inhibiting DDX17's aberrant interactions with disease proteins may provide benefit.

• Blocking the DDX17-alpha-synuclein interaction may reduce alpha-synuclein aggregation.
• Inhibiting DDX17-LRRK2 interaction could modulate LRRK2-mediated toxicity.

• Antisense oligonucleotides targeting DDX17 splicing targets could restore normal splicing patterns.
• Splicing modulator drugs may indirectly benefit DDX17-related pathways.

Biomarker Potential

DDX17 has potential as a biomarker:

• DDX17 levels in cerebrospinal fluid may reflect neuronal injury.
• The protein's phosphorylation state could indicate specific pathway activation.
• DDX17 autoantibodies have been detected in some neurodegenerative disease patients.

Drug Development Challenges

Developing DDX17-targeted therapies faces several challenges:

• Specificity: Achieving specificity for DDX17 over other DEAD-box helicases.
• Blood-Brain Barrier: Ensuring CNS penetration of therapeutic compounds.
• Dosage: Balancing restoration of DDX17 function without disrupting normal physiology.

Interacting Partners

Protein Partners

DDX17 interacts with numerous proteins:

| Partner | Function | Disease Relevance |
|---------|----------|-------------------|
| Alpha-synuclein | Protein aggregation | PD |
| LRRK2 | Kinase phosphorylation | PD |
| p53 | Transcriptional co-activation | Cancer, neuroprotection |
| NF-κB | Transcription factor | Neuroinflammation |
| FUS | RNA processing | ALS |
| TDP-43 | RNA processing | ALS |
| Estrogen receptor | Transcription | Neuroprotection |
| Drosha | miRNA processing | Gene regulation |

RNA Targets

DDX17 binds to numerous RNA species:

• mRNAs: Specific coding and non-coding transcripts.
• miRNAs: Primary and precursor miRNAs.
• lncRNAs: Long non-coding RNAs.
• snRNAs: Small nuclear RNAs involved in splicing.

Research Directions

Current Research Focus

Ongoing research is characterizing DDX17's roles in neurodegeneration:

• Structural Studies: Determining DDX17's structure in complex with disease-related proteins.
• Animal Models: Developing DDX17 knockout and mutant models to study in vivo functions.
• Therapeutic Screening: Identifying small molecules that modulate DDX17 activity.
• Biomarker Development: Validating DDX17 as a diagnostic or prognostic biomarker.

Future Directions

Future research should address:

• The mechanistic basis of DDX17's interactions with disease proteins.
• The cell-type specificity of DDX17 dysfunction.
• Translation of basic findings into clinical applications.
• Personalized medicine approaches based on DDX17 genotype.

See Also

• [DDX17 Gene](/genes/ddx17)
• [DEAD-box RNA helicases](/mechanisms/dead-box-helicases-neurodegeneration)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [LRRK2](/genes/lrrk2)
• [ALS pathogenesis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's disease mechanisms](/diseases/parkinsons-disease)
• [Stress granules in neurodegeneration](/mechanisms/stress-granules-als-ftd)
• [RNA processing in neurodegeneration](/mechanisms/rna-processing-neurodegeneration)

References